

Lucie H Clapp

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1342228/publications.pdf>

Version: 2024-02-01

87
papers

4,601
citations

117571

34
h-index

102432

66
g-index

89
all docs

89
docs citations

89
times ranked

5693
citing authors

#	ARTICLE	IF	CITATIONS
1	Prostanoid receptors in GtoPdb v.2021.2. IUPHAR/BPS Guide To Pharmacology CITE, 2021, 2021, .	0.2	2
2	The Prostacyclin Analogue, Treprostinil, Used in the Treatment of Pulmonary Arterial Hypertension, is a Potent Antagonist of TREK-1 and TREK-2 Potassium Channels. <i>Frontiers in Pharmacology</i> , 2021, 12, 705421.	1.6	1
3	THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G proteinâ€‘coupled receptors. <i>British Journal of Pharmacology</i> , 2021, 178, S27-S156.	2.7	337
4	Interaction between PGI2 and ET-1 pathways in vascular smooth muscle from Group-III pulmonary hypertension patients. <i>Prostaglandins and Other Lipid Mediators</i> , 2020, 146, 106388.	1.0	5
5	Bronchodilation induced by PGE 2 is impaired in Group III pulmonary hypertension. <i>British Journal of Pharmacology</i> , 2020, 177, 161-174.	2.7	13
6	Synthetic routes to treprostinil N-acyl methylsulfonamide. <i>Tetrahedron Letters</i> , 2020, 61, 151428.	0.7	1
7	International Union of Basic and Clinical Pharmacology. CIX. Differences and Similarities between Human and Rodent Prostaglandin E₂ Receptors (EP1â€‘4) and Prostacyclin Receptor (IP): Specific Roles in Pathophysiologic Conditions. <i>Pharmacological Reviews</i> , 2020, 72, 910-968.	7.1	26
8	Diverse Pharmacology of Prostacyclin Mimetics: Implications for Pulmonary Hypertension. , 2020, , 31-61.		4
9	Prostanoid receptors (version 2020.4) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide To Pharmacology CITE, 2020, 2020, .	0.2	3
10	Exploring the enzymatic degradation of poly(glycerol adipate). <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2019, 142, 377-386.	2.0	24
11	Altered cyclooxygenase-1 and enhanced thromboxane receptor activities underlie attenuated endothelial dilatory capacity of omental arteries in obesity. <i>Life Sciences</i> , 2019, 239, 117039.	2.0	6
12	THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G proteinâ€‘coupled receptors. <i>British Journal of Pharmacology</i> , 2019, 176, S21-S141.	2.7	519
13	<p>Selexipag in the management of pulmonary arterial hypertension: an update</p>. <i>Drug, Healthcare and Patient Safety</i> , 2019, Volume 11, 55-64.	1.0	8
14	Pharmacology of the single isomer, esuberaprost (beraprost-314d) on pulmonary vascular tone, IP receptors and human smooth muscle proliferation in pulmonary hypertension. <i>Biochemical Pharmacology</i> , 2019, 166, 242-252.	2.0	6
15	Adverse Events of Prostacyclin Mimetics in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2019, 8, 481.	1.0	14
16	Prostanoid receptors (version 2019.5) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide To Pharmacology CITE, 2019, 2019, .	0.2	2
17	Prostanoid receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide To Pharmacology CITE, 2019, 2019, .	0.2	0
18	RALINEPAG REDUCES PULMONARY VASCULAR RESISTANCE (PVR) IN A PHASE 2 STUDY CONFIRMING PRECLINICAL FINDINGS ON PROSTACYCLIN (IP) RECEPTORS IN HUMAN TISSUES. <i>Chest</i> , 2018, 154, 990A-991A.	0.4	1

#	ARTICLE	IF	CITATIONS
19	Improving Interpretation of Cardiac Phenotypes and Enhancing Discovery With Expanded Knowledge in the Gene Ontology. <i>Circulation Genomic and Precision Medicine</i> , 2018, 11, e001813.	1.6	24
20	Prostanoid EP2 Receptors Are Up-Regulated in Human Pulmonary Arterial Hypertension: A Key Anti-Proliferative Target for Treprostinil in Smooth Muscle Cells. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2372.	1.8	24
21	The Role of the K2P Channels TASK1, TREK1 and TREK2 in the Use of Treprostinil Therapy in Pulmonary Arterial Hypertension. <i>FASEB Journal</i> , 2018, 32, 567.6.	0.2	3
22	EP4 agonists have reduced bronchodilation activity in patients with Group III pulmonary hypertension. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018, WCP2018, OR20-2.	0.0	0
23	Impact of treprostinil on dynamin-related protein 1 (DRP1) and mitochondrial fragmentation in pulmonary arterial hypertension (PAH).., 2018, , .		1
24	Inotropic Effects of Prostacyclins on the Right Ventricle Are Abolished in Isolated Rat Hearts With Right-Ventricular Hypertrophy and Failure. <i>Journal of Cardiovascular Pharmacology</i> , 2017, 69, 1-12.	0.8	11
25	Prostacyclins have no direct inotropic effect on isolated atrial strips from the normal and pressure-overloaded human right heart. <i>Pulmonary Circulation</i> , 2017, 7, 339-347.	0.8	8
26	THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Overview. <i>British Journal of Pharmacology</i> , 2017, 174, S1-S16.	2.7	269
27	The non-prostanoid IP receptor agonist, APD811 (ralinepag) has potent antiproliferative and vasorelaxant properties in human pulmonary artery. , 2017, , .		0
28	The mechanistic basis of prostacyclin and its stable analogues in pulmonary arterial hypertension: Role of membrane versus nuclear receptors. <i>Prostaglandins and Other Lipid Mediators</i> , 2015, 120, 56-71.	1.0	69
29	Ex vivo relaxations of pulmonary arteries induced by prostacyclin mimetics are highly dependent of the precontractile agents. <i>Prostaglandins and Other Lipid Mediators</i> , 2015, 121, 46-52.	1.0	12
30	Differential action of beraprost isomers on prostacyclin (IP) receptors and PPAR γ in pulmonary arteries. , 2015, , .		0
31	Inhibition of Phosphodiesterase 2 Augments cGMP and cAMP Signaling to Ameliorate Pulmonary Hypertension. <i>Circulation</i> , 2014, 130, 496-507.	1.6	63
32	Differential actions of the prostacyclin analogues treprostinil and iloprost and the selexipag metabolite, MRE-269 (ACT-333679) in rat small pulmonary arteries and veins. <i>Prostaglandins and Other Lipid Mediators</i> , 2013, 106, 1-7.	1.0	21
33	A comparative study of PGI2 mimetics used clinically on the vasorelaxation of human pulmonary arteries and veins, role of the DP-receptor. <i>Prostaglandins and Other Lipid Mediators</i> , 2013, 107, 48-55.	1.0	37
34	Attenuated vascular responsiveness to K ⁺ channel openers in diabetes mellitus: the differential role of reactive oxygen species. <i>General Physiology and Biophysics</i> , 2013, 32, 527-534.	0.4	2
35	Inhibition of vascular adenosine triphosphate-sensitive potassium channels by sympathetic tone during sepsis. <i>Critical Care Medicine</i> , 2012, 40, 1261-1268.	0.4	5
36	Binding and activity of the prostacyclin receptor (IP) agonists, treprostinil and iloprost, at human prostanoid receptors: Treprostinil is a potent DP1 and EP2 agonist. <i>Biochemical Pharmacology</i> , 2012, 84, 68-75.	2.0	124

#	ARTICLE	IF	CITATIONS
37	BK Large Conductance Ca ²⁺ -Activated K ⁺ Channel-Deficient Mice are not Resistant to Hypotension and Display Reduced Survival Benefit Following Polymicrobial Sepsis. <i>Shock</i> , 2011, 35, 485-491.	1.0	13
38	Role of prostanoid IP and EP receptors in mediating vasorelaxant responses to PGI ₂ analogues in rat tail artery: Evidence for Gi/o modulation via EP ₃ receptors. <i>European Journal of Pharmacology</i> , 2011, 654, 258-265.	1.7	40
39	Smooth Muscle Proliferation and Role of the Prostacyclin (IP) Receptor in Idiopathic Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 182, 1161-1170.	2.5	124
40	Ca ²⁺ /calcineurin regulation of cloned vascular K ⁺ ATP channels: crosstalk with the protein kinase A pathway. <i>British Journal of Pharmacology</i> , 2009, 157, 554-564.	2.7	33
41	VARIABLE EFFECTS OF INHIBITING iNOS AND CLOSING THE VASCULAR ATP-SENSITIVE POTASSIUM CHANNEL (VIA ITS PORE-FORMING AND SULFONYLUREA RECEPTOR SUBUNITS) IN ENDOTOXIC SHOCK. <i>Shock</i> , 2009, 31, 535-541.	1.0	12
42	Different calcium mobilisation pathways underlie the changes in vascular reactivity to norepinephrine and vasopressin in septic shock. <i>Journal of Infection</i> , 2008, 57, 429-430.	1.7	0
43	Nuclear translocation of calcineurin A ¹ but not calcineurin A ² by platelet-derived growth factor in rat aortic smooth muscle. <i>American Journal of Physiology - Cell Physiology</i> , 2007, 292, C2213-C2225.	2.1	18
44	Endothelium-derived hyperpolarization factor (EDHF) is up-regulated in a pig model of acute liver failure. <i>Scandinavian Journal of Gastroenterology</i> , 2007, 42, 356-365.	0.6	2
45	Stoking Up BK ^{Ca} Channels in Hemorrhagic Shock. <i>Circulation Research</i> , 2007, 101, 436-438.	2.0	4
46	Differential effects of vasopressin and norepinephrine on vascular reactivity in a long-term rodent model of sepsis*. <i>Critical Care Medicine</i> , 2007, 35, 2337-2343.	0.4	73
47	Vasopressin: Mechanisms of action on the vasculature in health and in septic shock. <i>Critical Care Medicine</i> , 2007, 35, 33-40.	0.4	206
48	IP receptor-dependent activation of PPAR ¹ by stable prostacyclin analogues. <i>Biochemical and Biophysical Research Communications</i> , 2007, 360, 821-827.	1.0	59
49	Functional Expression of Inward Rectifier Potassium Channels in Cultured Human Pulmonary Smooth Muscle Cells: Evidence for a Major Role of Kir2.4 Subunits. <i>Journal of Membrane Biology</i> , 2006, 213, 19-29.	1.0	27
50	Evidence that inward rectifier K ⁺ channels mediate relaxation by the PGI ₂ receptor agonist cicaprost via a cyclic AMP-independent mechanism. <i>Cardiovascular Research</i> , 2006, 69, 107-115.	1.8	45
51	Role of KATP channels in sepsis. <i>Cardiovascular Research</i> , 2006, 72, 220-230.	1.8	76
52	The pore-forming subunit of the KATP channel is an important molecular target for LPS-induced vascular hyporeactivity in vitro. <i>British Journal of Pharmacology</i> , 2005, 144, 367-375.	2.7	32
53	Opportunities to Replace the Use of Animals in Sepsis Research. <i>ATLA Alternatives To Laboratory Animals</i> , 2005, 33, 641-648.	0.7	3
54	Reversal of life-threatening, drug-related potassium-channel syndrome by glibenclamide. <i>Lancet</i> , The, 2005, 365, 1873-1875.	6.3	28

#	ARTICLE	IF	CITATIONS
55	The large-conductance Ca ²⁺ -activated K ⁺ channel is essential for innate immunity. <i>Nature</i> , 2004, 427, 853-858.	13.7	185
56	Different molecular sites of action for the KATP channel inhibitors, PNU-99963 and PNU-37883A. <i>British Journal of Pharmacology</i> , 2003, 139, 122-128.	2.7	22
57	Do Anionic Phospholipids Serve as Cofactors or Second Messengers for the Regulation of Activity of Cloned ATP-Sensitive K ⁺ Channels?. <i>Circulation Research</i> , 2003, 93, 646-655.	2.0	38
58	The BK Channel. <i>Circulation Research</i> , 2003, 93, 893-895.	2.0	10
59	NO contributes to EDHF-like responses in rat small arteries: a role for NO stores. <i>Cardiovascular Research</i> , 2003, 57, 207-216.	1.8	53
60	Assembly Limits the Pharmacological Complexity of ATP-sensitive Potassium Channels. <i>Journal of Biological Chemistry</i> , 2002, 277, 13717-13723.	1.6	33
61	Differential Effects of Stable Prostacyclin Analogs on Smooth Muscle Proliferation and Cyclic AMP Generation in Human Pulmonary Artery. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2002, 26, 194-201.	1.4	211
62	The Molecular Composition of K ⁺ ATP Channels in Human Pulmonary Artery Smooth Muscle Cells and Their Modulation by Growth. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2002, 26, 135-143.	1.4	90
63	The molecular site of action of KATP channel inhibitors determines their ability to inhibit iNOS-mediated relaxation in rat aorta. <i>Cardiovascular Research</i> , 2002, 56, 154-163.	1.8	23
64	Terlipressin for norepinephrine-resistant septic shock. <i>Lancet</i> , The, 2002, 359, 1209-1210.	6.3	274
65	Substrate selectivity and sensitivity to inhibition by FK506 and cyclosporin A of calcineurin heterodimers composed of the I _± or I ₂ catalytic subunit. <i>FEBS Journal</i> , 2002, 269, 3540-3548.	0.2	44
66	Temporal variation in endotoxin-induced vascular hyporeactivity in a rat mesenteric artery organ culture model. <i>British Journal of Pharmacology</i> , 2001, 133, 351-360.	2.7	28
67	A mechanism for ATP-sensitive potassium channel diversity: Functional coassembly of two pore-forming subunits. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 729-734.	3.3	53
68	Calcium Modulation of Vascular Smooth Muscle ATP-Sensitive K ⁺ Channels. <i>Circulation Research</i> , 2000, 87, 1019-1025.	2.0	44
69	Effects of the adenylyl cyclase inhibitor SQ22536 on iloprost-induced vasorelaxation and cyclic AMP elevation in isolated guinea-pig aorta. <i>British Journal of Pharmacology</i> , 1999, 126, 845-847.	2.7	60
70	Evidence that Ca ²⁺ -activated K ⁺ channels play a major role in mediating the vascular effects of iloprost and cicaprost. <i>European Journal of Pharmacology</i> , 1998, 356, 215-224.	1.7	41
71	Potassium channels in the vasculature. <i>Current Opinion in Nephrology and Hypertension</i> , 1998, 7, 83-98.	1.0	40
72	Abnormal Activation of K ⁺ Channels Underlies Relaxation to Bacterial Lipopolysaccharide in Rat Aorta. <i>Biochemical and Biophysical Research Communications</i> , 1996, 224, 184-190.	1.0	49

#	ARTICLE	IF	CITATIONS
73	Regulation of glibenclamide-sensitive K ⁺ current by nucleotide phosphates in isolated rabbit pulmonary myocytes. <i>Cardiovascular Research</i> , 1995, 30, 460-468.	1.8	12
74	Properties of the ATP-sensitive K ⁺ current activated by levcromakalim in isolated pulmonary arterial myocytes. <i>Journal of Membrane Biology</i> , 1994, 140, 205-13.	1.0	12
75	Augmentation by intracellular ATP of the delayed rectifier current independently of the glibenclamide-sensitive K ⁺ current in rabbit arterial myocytes. <i>British Journal of Pharmacology</i> , 1994, 111, 972-974.	2.7	19
76	Calcium Channels and Vasodilation. <i>Advances in Molecular and Cell Biology</i> , 1994, , 21-41.	0.1	5
77	ATP-Sensitive K ⁺ Channels in the Pulmonary Vasculature. , 1993, , 129-139.		0
78	Both membrane stretch and fatty acids directly activate large conductance Ca ²⁺ -activated K ⁺ channels in vascular smooth muscle cells. <i>FEBS Letters</i> , 1992, 297, 24-28.	1.3	193
79	Modulation of calcium movements by nitroprusside in isolated vascular smooth muscle cells. <i>Pflügers Archiv European Journal of Physiology</i> , 1991, 418, 462-470.	1.3	109
80	Outward currents in rabbit pulmonary artery cells dissociated with a new technique. <i>Experimental Physiology</i> , 1991, 76, 677-693.	0.9	107
81	Dual regulation of M current in gastric smooth muscle cells: β -adrenergic-muscarinic antagonism. <i>Pflügers Archiv European Journal of Physiology</i> , 1990, 417, 291-302.	1.3	17
82	Substance P, like acetylcholine, augments one type of Ca ²⁺ current in isolated smooth muscle cells. <i>Pflügers Archiv European Journal of Physiology</i> , 1989, 413, 565-567.	1.3	19
83	Neurotransmitter Regulation of Ionic Channels in Freshly Dissociated Smooth Muscle Cells. <i>Annals of the New York Academy of Sciences</i> , 1988, 527, 346-359.	1.8	8
84	Regulation of one type of Ca ²⁺ current in smooth muscle cells by diacylglycerol and acetylcholine. <i>FASEB Journal</i> , 1988, 2, 2497-2504.	0.2	110
85	Acetylcholine increases voltage-activated Ca ²⁺ current in freshly dissociated smooth muscle cells.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1987, 84, 2092-2096.	3.3	80
86	Endothelial-dependent relaxant actions of carbachol and substance P in arterial smooth muscle. <i>British Journal of Pharmacology</i> , 1986, 87, 713-723.	2.7	106
87	The diverse effects of noradrenaline and other stimulants on ⁸⁶ Rb and ⁴² K efflux in rabbit and guinea-pig arterial muscle.. <i>Journal of Physiology</i> , 1984, 355, 43-63.	1.3	56